StreetInsider.com News Articles

Inventiva SA (IVA) Reiterated at Buy by Stifel as Ph.3 NATiV3 Trial Readout Approaches

Fri, 18 Sep 2026 07:49:41 -0400

Stifel analyst Annabel Samimy reiterated a Buy rating and $15.00 price target on Inventiva SA (NASDAQ: IVA).

The analyst commented, "We reiterate our Buy rating and $15 target price on IVA as we approach IVA’s Ph.3 NATiV3 pivotal trial readout of lanifibranor/Lani in MASH with a respectable level of confidence. Lani has generated very promising and consistent data, with strong anti-fibrotic activity supported by pan-PPAR benefits across the metabolic pathway. Our deep dive into the MoA of PPARs, the Ph.2b NATIVE data, modifications in NATiV3, and KOL commentary give us even greater confidence in Lani’s potential to reach the clinically important

Piper Sandler Reiterates Overweight on Inventiva SA (IVA) Following NYC Investor Dinner

Wed, 16 Sep 2026 08:26:58 -0400

Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $26.00 price target on Inventiva SA (NASDAQ: IVA).

The analyst commented: "Takeaways From Our Well-Attended NYC Investor Dinner; We had the opportunity to host IVA for a well-attended investor dinner in NYC. Accordingly, we walked away with reinforced confidence in lanifibranor's Ph3 NATiV3 topline 4Q26 to hit stat sig on its composite primary endpoint which mitigates high placebo responses and is de-risked by the 24% placebo-adjusted improvement observed in Ph2b NATIVE. With that, recognize the bogey is for lanifibranor to recapitulate the findings of NATIVE and demonstrate an 18% placebo-adjusted improvement

Inventiva SA (IVA) PT Raised to $14 at Guggenheim

Tue, 15 Sep 2026 07:06:58 -0400

(Updated - September 15, 2026 7:06 AM EDT)

Guggenheim analyst Etzer Darout raised the price target on Inventiva SA (NASDAQ: IVA) to $14.00 (from $11.00) while maintaining a Buy rating.

The analyst commented: "In our second report, we highlight our proprietary stats analysis alongside our conversations with mgmt that support a high likelihood of success at the 1200mg dose that are maintained across a variety of stress tests. We estimate a >90% probability of a positive p<0.02 result and the probability that lanifibranor 1200mg achieves a pbo-adjusted effect size at least comparable to Rezdiffra at >70%. Accordingly, we are updating both our

Inventiva SA (IVA) PT Raised to $14 at Guggenheim

Tue, 15 Sep 2026 07:06:58 -0400

(Updated - September 15, 2026 7:06 AM EDT)

Guggenheim analyst Etzer Darout raised the price target on Inventiva SA (NASDAQ: IVA) to $14.00 (from $11.00) while maintaining a Buy rating.

Form 6-K/A Inventiva S.A. For: Jul 30

Thu, 30 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260730/26844219.html

Form 6-K/A Inventiva S.A. For: Jul 30

Thu, 30 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260730/26844219.html

Form 6-K/A Inventiva S.A. For: Jul 30

Thu, 30 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260730/26844219.html

Form 6-K Inventiva S.A. For: Jul 29

Wed, 29 Jul 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260729/26835535.html

Form 6-K Inventiva S.A. For: Jul 29

Wed, 29 Jul 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260729/26835535.html

Form 6-K Inventiva S.A. For: Jul 29

Wed, 29 Jul 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260729/26835535.html

Cantor Fitzgerald Starts Inventiva SA (IVA) at Overweight

Fri, 17 Jul 2026 06:14:43 -0400

(Updated - July 17, 2026 6:14 AM EDT)

Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Inventiva SA (NASDAQ: IVA) with a Overweight rating.

The analyst commented: 'We are initiating coverage of Inventiva ("IVA") with an Overweight (OW) rating. IVA’s investment thesis is centered on lanifibranor (oral pan-PPAR agonist) currently in a P3 trial for F2-F3 (moderate to advanced fibrosis) MASH, with data anticipated in 4Q26. Most of the debate for lanifibranor (Lani) is centered on its safety and tolerability profile, such as weight gain and edema events seen in P2B. But we think these safety issues are overstated, particularly in the

Cantor Fitzgerald Starts Inventiva SA (IVA) at Overweight

Fri, 17 Jul 2026 06:14:43 -0400

(Updated - July 17, 2026 6:14 AM EDT)

Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Inventiva SA (NASDAQ: IVA) with a Overweight rating.

Form 6-K Inventiva S.A. For: Jul 09

Thu, 09 Jul 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260709/26753701.html

Form 6-K Inventiva S.A. For: Jul 09

Thu, 09 Jul 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260709/26753701.html

Form 6-K Inventiva S.A. For: Jul 09

Thu, 09 Jul 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260709/26753701.html

Form 6-K Inventiva S.A. For: Jul 02

Mon, 06 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260706/26732153.html

Form 6-K Inventiva S.A. For: Jul 02

Mon, 06 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260706/26732153.html

Form 6-K Inventiva S.A. For: Jul 02

Mon, 06 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260706/26732153.html

Form 6-K Inventiva S.A. For: Jun 12

Fri, 12 Jun 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260612/26641633.html

Form 6-K Inventiva S.A. For: Jun 12

Fri, 12 Jun 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260612/26641633.html

Form 6-K Inventiva S.A. For: Jun 12

Fri, 12 Jun 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260612/26641633.html

Form 6-K Inventiva S.A. For: Jun 12

Fri, 12 Jun 2026 06:23:00 -0400

si-local-file:///var/storage/secattach/20260612/26637997.html

Form 6-K Inventiva S.A. For: Jun 12

Fri, 12 Jun 2026 06:23:00 -0400

si-local-file:///var/storage/secattach/20260612/26637997.html

Form 6-K Inventiva S.A. For: Jun 12

Fri, 12 Jun 2026 06:23:00 -0400

si-local-file:///var/storage/secattach/20260612/26637997.html

Form 6-K Inventiva S.A. For: Jun 09

Tue, 09 Jun 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260609/26623955.html